# A Study Assessing KB407 for the Treatment of Cystic Fibrosis

> **NCT05504837** · PHASE1 · RECRUITING · sponsor: **Krystal Biotech, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **BIOLOGICAL:** KB407 (Nebulization)

## Key facts

- **NCT ID:** NCT05504837
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504837, "A Study Assessing KB407 for the Treatment of Cystic Fibrosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05504837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*